About Highfield
About HighField
HighField is developing next generation lipid-based structures that target to the tumor microenvironment and introduce gene therapy to treat chronic disease
Our mission is to develop drugs that significantly improve patient outcomes in a broad range of diseases. Our technology platform is based on lipid bilayers found in all the cells of our body. Lipids can self-assemble into fascinating structures and we have developed a process for designing structures that target the tumor microenvironment and others that introduce RNA for gene therapy. Our goal is to advance multiple strategies for navigating through the complexities of the human body to treat diseases.
The HighField Management Team
An enthusiastic and energetic team, well-positioned to deliver on the promise of unique lipid-based therapeutics as a new approach to treat diseases.
Yuhong Xu
Founder, CEO & CSO
From left: Yongchao Dai, Director of Business Management; Yan Xu, Head of Biologics Development; Samon Jin, Head of Research & Discovery; Yuhong Xu, CEO & CSO; Zhongming Luo, Sr Director Facilities; Filipe Huang, Head of Clinical Operations; Fengwei Xu, Head of Pharmaceutical Development; Lu Ye, Director of Quality Assurance.
English 
简体中文